Investigation on Diagnosis and Treatment of Helicobacter Pylori Infection by Gastroenterologists in Shandong Province
1 other identifier
observational
100
1 country
1
Brief Summary
Helicobacter pylori can lead to a variety of digestive system diseases.The eradication of Helicobacter pylori plays an importment role for the treatment of gastrointestinal ulcer and prevention of gastric cancer .Compared with other countries and regions in the world, the infection rate of Helicobacter pylori in China can reach more than 50%. The non-standard diagnosis and treatment of Helicobacter pylori greatly reduces its eradication rate and increases its drug resistance.Therefore, it is very important to strengthen the standardization of diagnosis and treatment to improve the eradication rate. The purpose of this study is to investigate the diagnosis and treatment status of Helicobacter pylori among gastroenterologists in general hospitals in Shandong Province.It can help us to understand the actual situation of diagnosis and treatment of Helicobacter pylori in hospitals at all levels, and to provide targeted diagnosis and treatment training for doctors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 2, 2021
CompletedFirst Posted
Study publicly available on registry
June 8, 2021
CompletedStudy Start
First participant enrolled
July 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 20, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 7, 2021
CompletedOctober 19, 2021
October 1, 2021
1 month
June 2, 2021
October 10, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the results of the questionnaires
the results of each question of the questionnaires
2 months
Eligibility Criteria
Stratified sampling was carried out from all the secondary and tertiary general hospitals in Shandong province, and 120 hospitals were selected.Exclude those without gastroenterology department and those that refused to sign the informed consent, and all gastroenterologists in the hospitals were investigated.
You may qualify if:
- All the gastroenterologists in secondary and tertiary general hospitals of Shandong province
You may not qualify if:
- A hospital that does not include gastroenterology
- Hospitals and gastroenterologists that refuse to sign informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Qilu hosipital
Jinan, Shandong, 257000, China
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, Director of gastroenterology department of Qilu hospital
Study Record Dates
First Submitted
June 2, 2021
First Posted
June 8, 2021
Study Start
July 10, 2021
Primary Completion
August 20, 2021
Study Completion
October 7, 2021
Last Updated
October 19, 2021
Record last verified: 2021-10